Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 11/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909345 | 0.85 | HPGD (0.47) | HPGDF10TSHRMEN1KMT2A | |
| SCHEMBL4908803 | 0.84 | HPGD (0.48) | HPGDF10TSHRMEN1KMT2A | |
| SCHEMBL4908815 | 0.84 | HPGD (0.42) | HPGDF10TSHRMEN1KMT2A | |
| SCHEMBL4906321 | 0.83 | MEN1 (0.43) | HPGDF10TSHRMEN1KMT2A | |
| SCHEMBL3087908 | 0.79 | HPGD (0.53) | HPGDF10TSHRKDM4EMAPK1 | |
| SCHEMBL1708736 | 0.78 | HPGD (0.52) | HPGDF10TSHRMEN1KMT2A | |
| SCHEMBL3089664 | 0.78 | HPGD (0.52) | HPGDF10TSHRKDM4EMAPK1 | |
| SCHEMBL4914554 | 0.78 | HPGD (0.40) | HPGDF10TSHRMEN1KMT2A | |
| SCHEMBL1277524 | 0.77 | HPGD (0.47) | HPGDF10TSHRKDM4E | |
| SCHEMBL4901722 | 0.77 | F10 (0.53) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | CYP11B2, CYP3A43, CYP11B1 | HPGD 4194/4885F10 2414/4885TSHR 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.